Bold opening: Southend residents feel forgotten as weight-loss options remain out of reach for many. Across the country, roughly 3.4 million people meet the eligibility criteria for Mounjaro, yet the NHS plans to treat only about 220,000 over three years. The government has also announced a £3,000 incentive for GP surgeries to prescribe the drug.
Even in a typical GP practice serving 6,000 patients, fewer than 20 individuals would qualify for the treatment in total, and year-one funding will cover only a portion of that group. This gap between eligibility and actual access highlights a stark disparity in who can benefit from this medical option.
The Liberal Democrats point to Southend as representing some of the country’s widest health inequalities, noting a 10.5-year life expectancy gap between the most and least wealthy areas among men. Obesity is a major contributing factor, yet many residents struggle to afford private healthcare or prescriptions, which can cost between £160 and £310 per month.
But here’s where the discussion gets tricky: access to weight-management therapies is entangled with budget limits, waiting lists, and regional health priorities. And this is the part most people miss—how policy choices shape who can actually access potentially life-changing treatments.
Do you think these restricted rollout plans strike the right balance between broad eligibility and sustainable funding, or should access to weight-loss medications be expanded more quickly to tackle health inequality in places like Southend? Share your thoughts in the comments.
